Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.62
JNJ's Cash-to-Debt is ranked lower than
66% of the 859 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. JNJ: 0.62 )
Ranked among companies with meaningful Cash-to-Debt only.
JNJ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.22 Max: 6.28
Current: 0.62
0.15
6.28
Equity-to-Asset 0.42
JNJ's Equity-to-Asset is ranked lower than
78% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. JNJ: 0.42 )
Ranked among companies with meaningful Equity-to-Asset only.
JNJ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.38  Med: 0.54 Max: 0.67
Current: 0.42
0.38
0.67
Debt-to-Equity 0.48
JNJ's Debt-to-Equity is ranked lower than
63% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. JNJ: 0.48 )
Ranked among companies with meaningful Debt-to-Equity only.
JNJ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06  Med: 0.26 Max: 0.58
Current: 0.48
0.06
0.58
Debt-to-EBITDA 1.22
JNJ's Debt-to-EBITDA is ranked higher than
62% of the 495 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. JNJ: 1.22 )
Ranked among companies with meaningful Debt-to-EBITDA only.
JNJ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.59  Med: 0.87 Max: 1.43
Current: 1.22
0.59
1.43
Interest Coverage 18.19
JNJ's Interest Coverage is ranked lower than
63% of the 648 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.08 vs. JNJ: 18.19 )
Ranked among companies with meaningful Interest Coverage only.
JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 18.19  Med: 34.53 Max: 39.32
Current: 18.19
18.19
39.32
Piotroski F-Score: 5
Altman Z-Score: 4.34
Beneish M-Score: -3.04
WACC vs ROIC
6.06%
2.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 23.00
JNJ's Operating Margin % is ranked higher than
87% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.97 vs. JNJ: 23.00 )
Ranked among companies with meaningful Operating Margin % only.
JNJ' s Operating Margin % Range Over the Past 10 Years
Min: 23  Med: 25.78 Max: 29.4
Current: 23
23
29.4
Net Margin % 1.89
JNJ's Net Margin % is ranked lower than
63% of the 802 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.32 vs. JNJ: 1.89 )
Ranked among companies with meaningful Net Margin % only.
JNJ' s Net Margin % Range Over the Past 10 Years
Min: 1.7  Med: 20.07 Max: 23.01
Current: 1.89
1.7
23.01
ROE % 2.37
JNJ's ROE % is ranked lower than
61% of the 832 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.94 vs. JNJ: 2.37 )
Ranked among companies with meaningful ROE % only.
JNJ' s ROE % Range Over the Past 10 Years
Min: 1.99  Med: 22.29 Max: 30.17
Current: 2.37
1.99
30.17
ROA % 0.99
JNJ's ROA % is ranked lower than
60% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. JNJ: 0.99 )
Ranked among companies with meaningful ROA % only.
JNJ' s ROA % Range Over the Past 10 Years
Min: 0.87  Med: 11.87 Max: 15.61
Current: 0.99
0.87
15.61
ROC (Joel Greenblatt) % 98.17
JNJ's ROC (Joel Greenblatt) % is ranked higher than
96% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.23 vs. JNJ: 98.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
JNJ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 65.66  Med: 93.44 Max: 119.25
Current: 98.17
65.66
119.25
3-Year Revenue Growth Rate 2.40
JNJ's 3-Year Revenue Growth Rate is ranked lower than
63% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. JNJ: 2.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
JNJ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 8.8 Max: 14.8
Current: 2.4
1.3
14.8
3-Year EBITDA Growth Rate 0.40
JNJ's 3-Year EBITDA Growth Rate is ranked lower than
65% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. JNJ: 0.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
JNJ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -6.6  Med: 9.8 Max: 19.3
Current: 0.4
-6.6
19.3
3-Year EPS without NRI Growth Rate -56.50
JNJ's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 663 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. JNJ: -56.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
JNJ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -56.5  Med: 12.4 Max: 34.2
Current: -56.5
-56.5
34.2
GuruFocus has detected 2 Warning Signs with Johnson & Johnson JNJ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» JNJ's 30-Y Financials

Financials (Next Earnings Date: 2019-04-17)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

JNJ Guru Trades in Q1 2018

Paul Tudor Jones 45,103 sh (New)
Signature Select Canadian Fund 49,900 sh (New)
Ken Fisher 12,639,622 sh (+4.22%)
Joel Greenblatt 390,826 sh (+62.87%)
Tom Russo 1,715 sh (+30.42%)
Lee Ainslie 98,820 sh (+46.36%)
Jeremy Grantham 4,941,803 sh (+14.41%)
Steven Cohen 388,716 sh (+728.82%)
Mairs and Power 2,221,696 sh (+1.36%)
First Pacific Advisors 10,400 sh (+7.22%)
Eaton Vance Worldwide Health Sciences Fund 496,664 sh (+43.03%)
Warren Buffett 327,100 sh (unchged)
Richard Snow 3,215 sh (unchged)
Tom Gayner 610,800 sh (unchged)
David Carlson 460,000 sh (unchged)
Steven Cohen 50,000 sh (unchged)
David Rolfe 5,550 sh (unchged)
Yacktman Fund 2,900,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
First Eagle Investment Sold Out
T Rowe Price Equity Income Fund 2,980,000 sh (-3.87%)
Tweedy Browne 2,221,515 sh (-1.19%)
Dodge & Cox 29,990 sh (-0.83%)
Charles Brandes 51,706 sh (-6.07%)
John Rogers 987,940 sh (-2.46%)
Murray Stahl 24,457 sh (-0.25%)
John Buckingham 60,066 sh (-4.48%)
PRIMECAP Management 909,475 sh (-1.29%)
Prem Watsa 148,650 sh (-1.72%)
Yacktman Asset Management 5,173,615 sh (-0.25%)
Jeff Auxier 100,030 sh (-0.42%)
Jim Simons 1,284,399 sh (-62.98%)
Caxton Associates 10,527 sh (-5.82%)
Diamond Hill Capital 1,831 sh (-4.09%)
Barrow, Hanley, Mewhinney & Strauss 9,435,767 sh (-5.91%)
Pioneer Investments 4,129,368 sh (-12.50%)
Mario Gabelli 190,751 sh (-8.02%)
Yacktman Focused Fund 1,430,000 sh (-1.38%)
Smead Capital Management, Inc. 299,498 sh (-0.03%)
» More
Q2 2018

JNJ Guru Trades in Q2 2018

Ray Dalio 109,950 sh (New)
Ken Fisher 13,118,604 sh (+3.79%)
T Rowe Price Equity Income Fund 3,020,000 sh (+1.34%)
Joel Greenblatt 414,164 sh (+5.97%)
Charles Brandes 54,647 sh (+5.69%)
John Rogers 1,002,162 sh (+1.44%)
Steven Cohen 416,400 sh (+7.12%)
Caxton Associates 10,704 sh (+1.68%)
Diamond Hill Capital 1,853 sh (+1.20%)
Pioneer Investments 4,524,003 sh (+9.56%)
David Rolfe 6,050 sh (+9.01%)
Jim Simons 3,740,300 sh (+191.21%)
Warren Buffett 327,100 sh (unchged)
Dodge & Cox 29,990 sh (unchged)
Richard Snow 3,215 sh (unchged)
Tom Russo 1,715 sh (unchged)
Tom Gayner 610,800 sh (unchged)
David Carlson 460,000 sh (unchged)
Yacktman Focused Fund 1,430,000 sh (unchged)
Yacktman Fund 2,900,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 496,664 sh (unchged)
First Pacific Advisors Sold Out
Tweedy Browne 2,177,149 sh (-2.00%)
Murray Stahl 24,233 sh (-0.92%)
John Buckingham 59,357 sh (-1.18%)
PRIMECAP Management 535,700 sh (-41.10%)
Prem Watsa 146,800 sh (-1.24%)
Lee Ainslie 73,820 sh (-25.30%)
Yacktman Asset Management 5,128,961 sh (-0.86%)
Jeremy Grantham 3,627,489 sh (-26.60%)
Paul Tudor Jones 18,120 sh (-59.83%)
Mairs and Power 2,207,186 sh (-0.65%)
Barrow, Hanley, Mewhinney & Strauss 8,957,593 sh (-5.07%)
Mario Gabelli 183,094 sh (-4.01%)
Tweedy Browne Global Value 860,002 sh (-0.67%)
Smead Capital Management, Inc. 294,232 sh (-1.76%)
Jeff Auxier 99,360 sh (-0.67%)
» More
Q3 2018

JNJ Guru Trades in Q3 2018

Diamond Hill Capital 2,037 sh (+9.93%)
John Rogers 1,024,773 sh (+2.26%)
Pioneer Investments 4,764,632 sh (+5.32%)
David Rolfe 6,300 sh (+4.13%)
Steven Cohen 575,937 sh (+38.31%)
John Buckingham 60,111 sh (+1.27%)
Dodge & Cox 31,690 sh (+5.67%)
Tweedy Browne Global Value 860,002 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 496,664 sh (unchged)
David Carlson 460,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Richard Snow 3,215 sh (unchged)
Prem Watsa 146,800 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Tom Russo Sold Out
Caxton Associates Sold Out
Paul Tudor Jones Sold Out
Yacktman Fund 2,700,000 sh (-6.90%)
Yacktman Focused Fund 1,350,000 sh (-5.59%)
T Rowe Price Equity Income Fund 2,995,000 sh (-0.83%)
Smead Capital Management, Inc. 287,012 sh (-2.45%)
Ken Fisher 11,259,081 sh (-14.17%)
Mario Gabelli 181,988 sh (-0.60%)
Yacktman Asset Management 4,846,668 sh (-5.50%)
Charles Brandes 52,829 sh (-3.33%)
Barrow, Hanley, Mewhinney & Strauss 7,290,924 sh (-18.61%)
PRIMECAP Management 295,700 sh (-44.80%)
Ray Dalio 77,815 sh (-29.23%)
Jim Simons 762,100 sh (-79.62%)
Jeremy Grantham 2,634,443 sh (-27.38%)
Mairs and Power 2,140,369 sh (-3.03%)
Tweedy Browne 2,139,592 sh (-1.73%)
Lee Ainslie 53,950 sh (-26.92%)
Murray Stahl 23,801 sh (-1.78%)
Joel Greenblatt 365,133 sh (-11.84%)
Jeff Auxier 99,060 sh (-0.30%)
Signature Select Canadian Fund 48,600 sh (-2.61%)
» More
Q4 2018

JNJ Guru Trades in Q4 2018

Tweedy Browne Global Value 860,002 sh (unchged)
Yacktman Fund 2,500,000 sh (-7.41%)
Yacktman Focused Fund 1,250,000 sh (-7.41%)
T Rowe Price Equity Income Fund 2,920,000 sh (-2.50%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:PFE, XSWX:ROG, XSWX:NOVN, NYSE:MRK, NYSE:ABBV, XTER:BAYN, LSE:GSK, XPAR:SAN, NYSE:LLY, LSE:AZN, NYSE:BMY, TSE:4503, TSE:4519, TSE:4578, TSE:4568, HKSE:01093, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867 » details
Traded in other countries:JNJ.Argentina, JNJ.Austria, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Headquarter Location:USA
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. Close to half of total revenue is generated within the United States.

Guru Investment Theses on Johnson & Johnson

Yacktman Fund Comments on Johnson & Johnson - Aug 09, 2018

J&J (NYSE:JNJ) declined in the second quarter after delivering strong returns in 2016 and 2017. It faces generic challenges to some of its major pharmaceuticals, but we believe J&J is well diversified and positioned to provide solid growth over time.





From Yacktman Fund (Trades, Portfolio)'s 2nd quarter 2018 shareholder letter.

Check out Donald Yacktman,Yacktman Asset Management latest stock trades

Jeff Auxier Comments on Johnson & Johnson - Aug 09, 2018

Johnson & Johnson (NYSE:JNJ)



One of only 22 companies to increase dividends every year for at least 50 consecutive years, Johnson & Johnson increased total sales in the first quarter 12.6% to over $20 billion. As the world’s largest medical conglomerate, they are well positioned to provide medicine and care for aging Baby Boomers.

From Jeff Auxier (Trades, Portfolio)'s second quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Johnson & Johnson - May 07, 2018

Johnson & Johnson (NYSE:JNJ)



Despite beating Wall Street’s fourth quarter earnings and revenue expectations, Johnson & Johnson lost investor confidence on a projected 2018 operational revenue growth of 3.5% to 4.5%. J&J’s $30B acquisition of Actelion last summer contributed 4.2% towards their Worldwide Pharmaceutical sales growth of 8.4% to $36.3B in the quarter.





From Jeff Auxier (Trades, Portfolio)'s first-quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Johnson & Johnson - Feb 06, 2018

Johnson & Johnson (NYSE:JNJ) saw a 10.3% growth in net sales as their Pharmaceutical segment–which represents 49% of overall sales–jumped 15% in the quarter. This has been due in part to the consistently growing sales of their lymphoma treatment, Imbruvica, increasing 46.7% year over year as additional implications continue to be approved by the FDA.







From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Johnson & Johnson - Aug 03, 2017

AAA rated Johnson & Johnson (NYSE:JNJ) is the world’s largest medical conglomerate. Johnson & Johnson just completed the acquisition of Actelion which gives them a sixth therapeutic area to address potential patients with pulmonary arterial hypertension. Johnson & Johnson expects the acquisition of Actelion to add $1.3 billion in sales for 2017.




From Jeff Auxier (Trades, Portfolio)'s second-quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

Top Ranked Articles about Johnson & Johnson

Johnson & Johnson Reports 4th-Quarter Financial Results Growth in the pharmaceutical segment offset the declines in the medical and consumer divisions
Johnson & Johnson (NYSE:JNJ) released its fourth-quarter earnings before the opening bell on Jan. 22, topping expectations on the back of superb sales of its psoriasis treatment and cancer drug. Sales in the consumer goods businesses improved only a little, while medical devices continued to struggle. Read more...
Johnson & Johnson Shares Fall on Disappointing 2019 Outlook Company posts 4th-quarter earnings beat
Health care conglomerate Johnson & Johnson (NYSE:JNJ) reported fourth-quarter and full-year 2018 results before the opening bell on Tuesday. Read more...
JOHNSON & JOHNSON INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Johnson & Johnson - JNJ
Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention
Johnson & Johnson Completes Acquisition of Ci:z Holdings Co., Ltd.
Johnson & Johnson Recommends Rejection Of Below-Market "Mini-Tender" Offer By Peer & Peri LLC
Johnson & Johnson Announces completion of Offer for Ci:z Holdings Co., Ltd.
Dr. Paul Janssen Award for Biomedical Research Issues 2019 Call for Nominations to Celebrate Champions of Science
Johnson & Johnson Might Take a While to Recover With No Bottom in Sight Despite the crash in the stock price post asbestos concerns, the company continues to be overvalued with the added risk of lawsuit settlements
Johnson & Johnson (NYSE:JNJ) has always been a premier blue-chip stock that has given good returns to investors over the years through both dividends and price appreciation. However, the company’s stock recently experienced one of its worst historical falls when it was revealed that the talc in its baby powder contained asbestos, which could cause cancer. Read more...
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2019

Ratios

vs
industry
vs
history
PE Ratio 252.53
JNJ's PE Ratio is ranked lower than
98% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.77 vs. JNJ: 252.53 )
Ranked among companies with meaningful PE Ratio only.
JNJ' s PE Ratio Range Over the Past 10 Years
Min: 10.5  Med: 18.52 Max: 368.4
Current: 252.53
10.5
368.4
Forward PE Ratio 15.17
JNJ's Forward PE Ratio is ranked higher than
69% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.60 vs. JNJ: 15.17 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 252.53
JNJ's PE Ratio without NRI is ranked lower than
97% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.20 vs. JNJ: 252.53 )
Ranked among companies with meaningful PE Ratio without NRI only.
JNJ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.5  Med: 18.52 Max: 368.4
Current: 252.53
10.5
368.4
Price-to-Owner-Earnings 20.13
JNJ's Price-to-Owner-Earnings is ranked higher than
73% of the 324 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.95 vs. JNJ: 20.13 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
JNJ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.19  Med: 17.79 Max: 24.56
Current: 20.13
10.19
24.56
PB Ratio 5.36
JNJ's PB Ratio is ranked lower than
79% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.64 vs. JNJ: 5.36 )
Ranked among companies with meaningful PB Ratio only.
JNJ' s PB Ratio Range Over the Past 10 Years
Min: 2.68  Med: 3.71 Max: 6.57
Current: 5.36
2.68
6.57
PS Ratio 4.32
JNJ's PS Ratio is ranked lower than
62% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. JNJ: 4.32 )
Ranked among companies with meaningful PS Ratio only.
JNJ' s PS Ratio Range Over the Past 10 Years
Min: 2.16  Med: 3.6 Max: 5.29
Current: 4.32
2.16
5.29
Price-to-Free-Cash-Flow 19.04
JNJ's Price-to-Free-Cash-Flow is ranked higher than
69% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.84 vs. JNJ: 19.04 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
JNJ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.29  Med: 18.15 Max: 24.33
Current: 19.04
10.29
24.33
Price-to-Operating-Cash-Flow 15.94
JNJ's Price-to-Operating-Cash-Flow is ranked higher than
65% of the 392 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.00 vs. JNJ: 15.94 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
JNJ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.99  Med: 14.78 Max: 19.51
Current: 15.94
8.99
19.51
EV-to-EBIT 19.35
JNJ's EV-to-EBIT is ranked lower than
54% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.85 vs. JNJ: 19.35 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 13.8 Max: 22.6
Current: 19.35
7.8
22.6
EV-to-EBITDA 14.01
JNJ's EV-to-EBITDA is ranked higher than
55% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.24 vs. JNJ: 14.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 11.4 Max: 17.3
Current: 14.01
6.7
17.3
EV-to-Revenue 4.36
JNJ's EV-to-Revenue is ranked lower than
61% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. JNJ: 4.36 )
Ranked among companies with meaningful EV-to-Revenue only.
JNJ' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 3.5 Max: 5.5
Current: 4.36
2.1
5.5
PEG Ratio 38.83
JNJ's PEG Ratio is ranked lower than
98% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. JNJ: 38.83 )
Ranked among companies with meaningful PEG Ratio only.
JNJ' s PEG Ratio Range Over the Past 10 Years
Min: 1.17  Med: 2.27 Max: 62.29
Current: 38.83
1.17
62.29
Shiller PE Ratio 26.58
JNJ's Shiller PE Ratio is ranked higher than
58% of the 252 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.75 vs. JNJ: 26.58 )
Ranked among companies with meaningful Shiller PE Ratio only.
JNJ' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.52  Med: 21.22 Max: 31.55
Current: 26.58
15.52
31.55
Current Ratio 1.72
JNJ's Current Ratio is ranked lower than
66% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. JNJ: 1.72 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.91 Max: 3.08
Current: 1.72
1.2
3.08
Quick Ratio 1.40
JNJ's Quick Ratio is ranked lower than
63% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. JNJ: 1.40 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.47 Max: 2.68
Current: 1.4
0.94
2.68
Days Inventory 119.44
JNJ's Days Inventory is ranked lower than
51% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.80 vs. JNJ: 119.44 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 118.92 Max: 137.6
Current: 119.44
100.19
137.6
Days Sales Outstanding 63.01
JNJ's Days Sales Outstanding is ranked higher than
66% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.76 vs. JNJ: 63.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 58.66 Max: 64.41
Current: 63.01
53.94
64.41
Days Payable 93.34
JNJ's Days Payable is ranked higher than
55% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.32 vs. JNJ: 93.34 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 93.34  Med: 109.43 Max: 147.94
Current: 93.34
93.34
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.77
JNJ's Dividend Yield % is ranked higher than
72% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. JNJ: 2.77 )
Ranked among companies with meaningful Dividend Yield % only.
JNJ' s Dividend Yield % Range Over the Past 10 Years
Min: 2.25  Med: 2.84 Max: 3.84
Current: 2.77
2.25
3.84
Dividend Payout Ratio 5.90
JNJ's Dividend Payout Ratio is ranked lower than
99% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. JNJ: 5.90 )
Ranked among companies with meaningful Dividend Payout Ratio only.
JNJ' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.39  Med: 0.53 Max: 7.06
Current: 5.9
0.39
7.06
3-Year Dividend Growth Rate 6.40
JNJ's 3-Year Dividend Growth Rate is ranked lower than
52% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. JNJ: 6.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
JNJ' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 6.4  Med: 13.4 Max: 17.2
Current: 6.4
6.4
17.2
Forward Dividend Yield % 2.75
JNJ's Forward Dividend Yield % is ranked higher than
71% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. JNJ: 2.75 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.83
JNJ's 5-Year Yield-on-Cost % is ranked higher than
72% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. JNJ: 3.83 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
JNJ' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.11  Med: 3.93 Max: 5.31
Current: 3.83
3.11
5.31
3-Year Average Share Buyback Ratio 1.20
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.30 vs. JNJ: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: 0.3 Max: 2.4
Current: 1.2
-4.3
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.70
JNJ's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
57% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. JNJ: 1.70 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
JNJ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.85  Med: 1.64 Max: 3.51
Current: 1.7
0.85
3.51
Price-to-Intrinsic-Value-DCF (Earnings Based) 23.59
JNJ's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
100% of the 110 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. JNJ: 23.59 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
JNJ' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.57  Med: 1.31 Max: 32.64
Current: 23.59
0.57
32.64
Price-to-Median-PS-Value 1.20
JNJ's Price-to-Median-PS-Value is ranked lower than
73% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.94 vs. JNJ: 1.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
JNJ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 0.97 Max: 1.68
Current: 1.2
0.48
1.68
Earnings Yield (Greenblatt) % 5.15
JNJ's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. JNJ: 5.15 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
JNJ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.4  Med: 7.3 Max: 12.9
Current: 5.15
4.4
12.9
Forward Rate of Return (Yacktman) % 9.13
JNJ's Forward Rate of Return (Yacktman) % is ranked higher than
51% of the 421 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.96 vs. JNJ: 9.13 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
JNJ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2  Med: 12.4 Max: 17.4
Current: 9.13
2
17.4

More Statistics

Revenue (TTM) (Mil) $81,382.00
EPS (TTM) $ 0.51
Beta0.62
Volatility19.11%
52-Week Range $118.62 - 148.99
Shares Outstanding (Mil)2,681.98

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 81,331 82,788 85,370
EBIT (Mil $) 25,511 26,613 28,775
EBITDA (Mil $) 30,799 31,988 34,106
EPS ($) 7.10 7.76 8.21
EPS without NRI ($) 7.10 7.76 8.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.38%
Dividends per Share ($) 3.58 3.79 3.96

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

» More Articles for JNJ

Headlines

Articles On GuruFocus.com
Johnson & Johnson Reports 4th-Quarter Financial Results Jan 22 2019 
Johnson & Johnson Shares Fall on Disappointing 2019 Outlook Jan 22 2019 
JOHNSON & JOHNSON INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, Jan 18 2019 
Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Jan 17 2019 
Johnson & Johnson Completes Acquisition of Ci:z Holdings Co., Ltd. Jan 17 2019 
Johnson & Johnson Recommends Rejection Of Below-Market "Mini-Tender" Offer By Peer & Peri LLC Jan 11 2019 
Johnson & Johnson Announces completion of Offer for Ci:z Holdings Co., Ltd. Jan 11 2019 
Dr. Paul Janssen Award for Biomedical Research Issues 2019 Call for Nominations to Celebrate Champio Jan 10 2019 
US Market Indexes Continue Gains, Dow Adds 1.09% Tuesday Jan 08 2019 
Johnson & Johnson Might Take a While to Recover With No Bottom in Sight Jan 07 2019 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}